Renal manifestations in the metabolic syndrome

被引:126
作者
Locatelli, Francesco [1 ]
Pozzoni, Pietro [1 ]
Del Vecchio, Lucia [1 ]
机构
[1] A Manzoni Hosp, Dept Nephrol & Dialysis, I-23900 Lecce, Italy
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷 / 04期
关键词
D O I
10.1681/ASN.2005121332
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The metabolic syndrome, which is characterized by obesity, serum lipid profile alterations, hypertension, and fasting hyperglycemia, is very common in developed countries, and its prevalence is likely to increase. Chronic kidney disease (CKD) also has become a significant public health problem because it affects a considerable proportion of the adult population and is a major risk factor for cardiovascular disease and premature death. Although it is widely known that the metabolic syndrome is a major risk factor for the development of type 2 diabetes and cardiovascular disease, its precise relationship with the risk for renal impairment only recently has been clarified: Patients with the metabolic syndrome are at significantly higher risk for microalbuminuria and/or CKD, and the level of risk is related to the number of components of the syndrome itself. Although it is difficult to discriminate the detrimental renal effects of the metabolic syndrome from those of hypertension and impaired glucose metabolism, its other aspects (particularly obesity) may favor independently the development of renal abnormalities and may be considered new modifiable risk factors for CKD. These observations provide a rationale for intervention studies that aim to verify whether treating the many components of the metabolic syndrome can effectively prevent the development and progression of renal damage.
引用
收藏
页码:S81 / S85
页数:5
相关论文
共 38 条
[31]   Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].
Turner, RC ;
Holman, RR ;
Cull, CA ;
Stratton, IM ;
Matthews, DR ;
Frighi, V ;
Manley, SE ;
Neil, A ;
McElroy, K ;
Wright, D ;
Kohner, E ;
Fox, C ;
Hadden, D ;
Mehta, Z ;
Smith, A ;
Nugent, Z ;
Peto, R ;
Adlel, AI ;
Mann, JI ;
Bassett, PA ;
Oakes, SF ;
Dornan, TL ;
Aldington, S ;
Lipinski, H ;
Collum, R ;
Harrison, K ;
MacIntyre, C ;
Skinner, S ;
Mortemore, A ;
Nelson, D ;
Cockley, S ;
Levien, S ;
Bodsworth, L ;
Willox, R ;
Biggs, T ;
Dove, S ;
Beattie, E ;
Gradwell, M ;
Staples, S ;
Lam, R ;
Taylor, F ;
Leung, L ;
Carter, RD ;
Brownlee, SM ;
Fisher, KE ;
Islam, K ;
Jelfs, R ;
Williams, PA ;
Williams, FA ;
Sutton, PJ .
LANCET, 1998, 352 (9131) :837-853
[32]   METAANALYSIS OF EFFECTS OF INTENSIVE BLOOD-GLUCOSE CONTROL ON LATE COMPLICATIONS OF TYPE-I DIABETES [J].
WANG, PH ;
LAU, J ;
CHALMERS, TC .
LANCET, 1993, 341 (8856) :1306-1309
[33]   NEPHROTIC SYNDROME - COMPLICATION OF MASSIVE OBESITY [J].
WEISINGE.JR ;
KEMPSON, RL ;
ELDRIDGE, FL ;
SWENSON, RS .
ANNALS OF INTERNAL MEDICINE, 1974, 81 (04) :440-447
[34]   Clustering of metabolic factors and coronary heart disease [J].
Wilson, PWF ;
Kannel, WB ;
Silbershatz, H ;
D'Agostino, RB .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (10) :1104-1109
[35]   The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity [J].
Wisse, BE .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (11) :2792-2800
[36]   Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells:: Potential role in glomerulosclerosis [J].
Wolf, G ;
Hamann, A ;
Han, DC ;
Helmchen, U ;
Thaiss, F ;
Ziyadeh, FN ;
Stahl, RAK .
KIDNEY INTERNATIONAL, 1999, 56 (03) :860-872
[37]  
Xue JL, 2001, J AM SOC NEPHROL, V12, P2753, DOI 10.1681/ASN.V12122753
[38]  
2001, JAMA, V28, P2486